via Phys.org
Antibody building blocks stuck together with bacterial superglue can protect against bunyaviruses, and herald a new approach to developing antibodies to fight emerging viruses.
Synthetic antibodies constructed using bacterial superglue can neutralise potentially lethal viruses, according to a study published last week in eLife.
The findings provide a new approach to preventing and treating infections of emerging viruses and could also potentially be used in therapeutics for other diseases.
Bunyaviruses are mainly carried by insects, such as mosquitoes, and can have devastating effects on animal and human health. The World Health Organization has included several of these viruses on the Blueprint list of pathogens likely to cause epidemics in humans in the face of absent or insufficient countermeasures.
“After vaccines, antiviral and antibody therapies are considered the most effective tools to fight emerging life-threatening virus infections,” explains author Paul Wichgers Schreur, a senior scientist of Wageningen Bioveterinary Research, The Netherlands. “Specific antibodies called VHHs have shown great promise in neutralising a respiratory virus of infants. We investigated if the same antibodies could be effective against emerging bunyaviruses.”
Antibodies naturally found in humans and most other animals are composed of four ‘chains’ – two heavy and two light. VHHs are the antigen-binding domains of heavy chain-only antibodies found in camelids and are fully functional as a single domain. This makes VHHs smaller and able to bind to pathogens in ways that human antibodies cannot. Furthermore, the single chain nature makes them perfect building blocks for the construction of multifunctional complexes.
In this study, the researchers immunised llamas with two prototypes of bunyaviruses, the Rift Valley fever virus (RVFV) and the Schmallenberg virus (SBV), to generate VHHs that target an important part of the virus’ infective machinery, the glycoprotein head. They found that RVFV and SBV VHHs recognised different regions within the glycoprotein structure.
When they tested whether the VHHs could neutralise the virus in a test tube, they found that single VHHs could not do the job. Combining two different VHHs had a slightly better neutralising effect against SBV, but this was not effective for RVFV. To address this, the team used ‘superglue’ derived from bacteria to stick multiple VHHs together as a single antibody complex. The resulting VHH antibody complexes efficiently neutralised both viruses, but only if the VHHs in the complex targeted more than one region of the virus glycoprotein head.
Studies in mice with the best performing VHH antibody complexes showed that these complexes were able to prevent death. The number of viruses in the blood of the treated mice was also substantially reduced compared with the untreated animals.
To work in humans optimally, antibodies need to have all the effector functions of natural human antibodies. To this end, the team constructed llama-human chimeric antibodies. Administering a promising chimeric antibody to mice before infection prevented lethal disease in 80% of the animals, and treating them with the antibody after infection prevented mortality in 60%.
“We’ve harnessed the beneficial characteristics of VHHs in combination with bacterial superglues to develop highly potent virus neutralising complexes,” concludes senior author Jeroen Kortekaas, Senior Scientist at Wageningen Bioveterinary Research, and Professor of the Laboratory of Virology, Wageningen University, The Netherlands. “Our approach could aid the development of therapeutics for bunyaviruses and other viral infections, as well as diseases including cancer.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Synthetic antibodies
- IISc researchers design an antigen that boosts antibody production against cancer cells
IISc researchers design an antigen that boosts antibody production against cancer cells: Nandita Vijayasimha, Bengaluru Thursday, April 25, 2024, 08:00 Hrs [IST] Researchers at th ...
- Monoclonal Antibodies in Rheumatoid Arthritis
No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).
- BigHat Biosciences Enters Into Strategic Collaboration to Leverage Machine Learning in Antibody Discovery & Design
BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a ...
- IISc develops synthetic antigens that boost production of antibodies to fight cancer cells
Bengaluru, have developed synthetic (compound) antigens that can boost the production of antibodies that fight against cancer cells. The antigen is carried to the lymph node through serum albumin, ...
- Are Monoclonal Antibodies the Future of Long COVID Treatments?
Dr. Nancy Klimas, director of the Institute for Neuro-Immune Medicine at Nova Southeastern University, explains the great potential of monoclonal antibodies in treating long COVID.
Go deeper with Google Headlines on:
Synthetic antibodies
[google_news title=”” keyword=”synthetic antibodies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Virus neutralising complexes
- Federal avian flu response kicks into gear
Federal agriculture and health officials have increased communication with the public in recent days about an outbreak of avian influenza in cows across multiple states.
- Lessons for dengue vaccines from a human challenge study
Dengue is an acute mosquito-borne illness that is caused by four different dengue viruses (serotypes 1–4). More than half the world's population lives at risk of dengue. Among the different approaches ...
- Giant virus discovered in wastewater treatment plant infects deadly parasite
The single-celled organism Naegleria fowleri ranks among the deadliest human parasites. Researchers around Matthias Horn and Patrick Arthofer from the Center for Microbiology and Environmental Systems ...
- Virtual Viruses Reveal Complex Genomic Dynamics
A virus may be microscopic, but it contains thousands of nucleic acid bases strategically packaged into a protein shell. Knowing how the virus organizes these vast information stores in a compact ...
- DNA vaccine against Zika performs well in tests on mice
In Brazil, researchers at the University of São Paulo (USP) and the Pernambuco division of Oswaldo Cruz Foundation (FIOCRUZ) are developing a Zika vaccine. The formulation was tested on mice and found ...
Go deeper with Google Headlines on:
Virus neutralising complexes
[google_news title=”” keyword=”virus neutralising complexes” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]